Medical castration with gonadotropin-releasing hormone agonists (GnRH-As) in prostate cancer patients dates back to 1982 with leuprolide and goserelin the 2 most commonly used GnRH-As [34]. Here, GNRH1 is linked to prostate carcinoma.